BridgeBio Oncology Therapeutics, Inc. (BBOT) Ownership
BBOT ownership summary
as of October 18, 2026- Institutions
- 71.1% of shares outstanding
- Insiders
- 27.12% of shares outstanding
- Shares outstanding
- 80.2M
- Float
- 35.8M shares available to trade
- Short interest
- 11.82% 3.4M shares short
- Days to cover
- 4.72 short interest down 6.1% vs prior month
- Institutions 71.11%
- Insiders 27.12%
- Other investors 1.77%
BBOT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Cormorant Asset Management, LLC | 22.30% | 17.9M | $50.4M | — | June 30, 2026 |
| 2 | Deerfield Management Co | 6.09% | 4.9M | $13.8M | — | June 30, 2026 |
| 3 | Omega Fund Management LLC | 4.10% | 3.3M | $9.3M | — | June 30, 2026 |
| 4 | Alphabet Inc | 3.52% | 2.8M | $8.0M | — | June 30, 2026 |
| 5 | EcoR1 Capital, LLC | 3.52% | 2.8M | $8.0M | — | June 30, 2026 |
| 6 | Wellington Management Company LLP | 3.48% | 2.8M | $7.9M | −29,046 (−1.0%) | June 30, 2026 |
| 7 | Enavate Sciences GP, LLC | 3.28% | 2.6M | $7.4M | — | June 30, 2026 |
| 8 | Citadel Advisors Llc | 3.27% | 2.6M | $7.4M | +89,065 (+3.5%) | June 30, 2026 |
| 9 | Novo A/S | 2.81% | 2.2M | $6.3M | +64,077 (+2.9%) | June 30, 2026 |
| 10 | BlackRock Inc | 2.69% | 2.2M | $6.1M | +65,743 (+3.1%) | June 30, 2026 |
| 11 | Vanguard Capital Management, LLC | 2.50% | 2.0M | $5.7M | +1.5M (+272.5%) | June 30, 2026 |
| 12 | LAURION CAPITAL MANAGEMENT LP | 2.50% | 2.0M | $5.6M | +80,045 (+4.2%) | June 30, 2026 |
| 13 | Armistice Capital, LLC | 2.20% | 1.8M | $5.0M | +436,000 (+32.8%) | June 30, 2026 |
| 14 | State Street Corp | 1.29% | 1.0M | $2.9M | +810,291 (+358.1%) | June 30, 2026 |
| 15 | Aisling Capital Management LP | 1.27% | 1.0M | $2.9M | — | June 30, 2026 |
| 16 | Opaleye Management Inc | 0.87% | 700K | $2.0M | +646,718 (+1,213.8%) | June 30, 2026 |
| 17 | Geode Capital Management, LLC | 0.78% | 622K | $1.8M | +43,117 (+7.4%) | June 30, 2026 |
| 18 | Granahan Investment Management Inc.. | 0.70% | 559K | $1.6M | +327,486 (+141.7%) | June 30, 2026 |
| 19 | Sphera Funds Management Ltd. | 0.57% | 461K | $1.3M | +460,985 (0.0%) | June 30, 2026 |
| 20 | Adage Capital Partners Gp LLC | 0.50% | 400K | $1.1M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 4.5M shares and 1 cut 29K.
BBOT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 1.77% | 1.4M | $4.0M | — | August 31, 2026 |
| 2 | BlackRock Health Sciences Opps Inv A | 1.10% | 883K | $2.5M | +209,287 (+31.1%) | August 31, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 0.83% | 663K | $1.9M | −12,650 (−1.9%) | September 30, 2026 |
| 4 | iShares Biotechnology ETF | 0.47% | 373K | $1.1M | −2,832 (−0.8%) | September 30, 2026 |
| 5 | BlackRock Health Sciences Term Trust | 0.33% | 264K | $743,547 | — | June 30, 2026 |
| 6 | Fidelity Extended Market Index | 0.30% | 241K | $679,448 | +914 (+0.4%) | August 31, 2026 |
| 7 | Fidelity Select Biotechnology | 0.30% | 240K | $677,646 | — | August 31, 2026 |
| 8 | Schwab US Small-Cap ETF™ | 0.28% | 226K | $637,616 | +144 (+0.1%) | September 30, 2026 |
| 9 | T. Rowe Price Health Sciences | 0.28% | 223K | $627,484 | — | August 31, 2026 |
| 10 | Royce Micro-Cap Trust | 0.26% | 211K | $594,608 | +62,863 (+42.5%) | June 30, 2026 |
| 11 | Schroder Global Healthcare A Acc | 0.21% | 166K | $468,013 | — | August 31, 2026 |
| 12 | Victory Small Cap Stock | 0.17% | 133K | $373,760 | +78,777 (+146.5%) | June 30, 2026 |
| 13 | Tema Oncology ETF | 0.12% | 100K | $281,295 | — | September 30, 2026 |
| 14 | Fidelity Total Market Index | 0.11% | 90K | $254,660 | — | August 31, 2026 |
| 15 | Royce Micro-Cap Invmt | 0.11% | 88K | $247,080 | +18,830 (+27.4%) | June 30, 2026 |
| 16 | Schroder ISF Hlthcr Innovt IZ Acc USD | 0.10% | 82K | $230,631 | +3,305 (+4.2%) | August 31, 2026 |
| 17 | Fidelity Series Total Market Index | 0.09% | 74K | $208,889 | +1,142 (+1.6%) | August 31, 2026 |
| 18 | BlackRock Health Sciences | 0.07% | 60K | $169,285 | — | June 30, 2026 |
| 19 | Pacific Select Health Sciences I | 0.05% | 43K | $122,363 | — | September 30, 2026 |
| 20 | Virtus LifeSci Biotech Clinical Trls ETF | 0.05% | 41K | $115,468 | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
BBOT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns BBOT
Institutional investors own 71.1% of BridgeBio Oncology Therapeutics's shares and insiders 27.12%. The largest holder is Cormorant Asset Management, LLC with 22.30% of the shares (17.9M), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 1 reduced their stake in the latest filings. Short interest is 11.82% of the float, or 4.72 days of average trading volume. The share count rose 290.5% since 2022.
Related: BBOT analyst forecast, BBOT key metrics. See the BBOT stock overview for the latest quote and news.
BBOT ownership FAQ
Who owns the most BridgeBio Oncology Therapeutics stock?
The largest shareholders of BridgeBio Oncology Therapeutics are Cormorant Asset Management, LLC (22.30%), Deerfield Management Co (6.09%), Omega Fund Management LLC (4.10%), Alphabet Inc (3.52%), EcoR1 Capital, LLC (3.52%).
What percentage of BridgeBio Oncology Therapeutics is owned by institutions?
Institutions hold 71.1% of BridgeBio Oncology Therapeutics's shares outstanding; insiders hold 27.12%.
Which funds own BridgeBio Oncology Therapeutics?
The largest fund holders of BridgeBio Oncology Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (1.77%), BlackRock Health Sciences Opps Inv A (1.10%), State Street® SPDR® S&P® Biotech ETF (0.83%), iShares Biotechnology ETF (0.47%), BlackRock Health Sciences Term Trust (0.33%).
What is BridgeBio Oncology Therapeutics's short interest?
3.4M shares of BridgeBio Oncology Therapeutics were sold short, 11.82% of the float; at the average daily volume it would take 4.72 days to cover.
How many shares of BridgeBio Oncology Therapeutics are outstanding?
BridgeBio Oncology Therapeutics has 80.2M shares outstanding, of which 35.8M are in the public float.